Update onEpidermal Growth Factor ReceptorMutations in Non–Small Cell Lung Cancer
Top Cited Papers
Open Access
- 15 December 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (24) , 7232-7241
- https://doi.org/10.1158/1078-0432.ccr-06-0658
Abstract
In 2004, several investigators reported that somatic mutations in the epidermal growth factor receptor gene were associated with clinical responses to erlotinib and gefitinib in patients with non–small cell lung cancer. Since then, multiple groups have examined the biological properties that such mutations confer as well as the clinical relevance of these mutations in patients with non–small cell lung cancer. Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions.Keywords
This publication has 100 references indexed in Scilit:
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorPublished by Elsevier ,2006
- Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptorsGenes & Development, 2006
- Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitorsProceedings of the National Academy of Sciences, 2006
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancerBritish Journal of Cancer, 2006
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabPublished by Elsevier ,2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004